Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
60 hedge funds and large institutions have $309M invested in Dova Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 13 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
12% more capital invested
Capital invested by funds: $275M → $309M (+$33.5M)
9% more funds holding
Funds holding: 55 → 60 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.5M |
| 2 |
PA
Perceptive Advisors
New York
|
+$9.39M |
| 3 |
NC
Nexthera Capital
New York
|
+$6.87M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.14M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.7M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$11.4M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
-$5.91M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.99M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$3.39M |
DOVA Hedge Fund Activity: Q2 2018 in Review
60 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q2 2018, worth a combined $309M — up 12% from $275M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DOVA positions and 13 closed out — a net gain of 5 holders — while 27 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $13.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $11.7M sold.
- 60 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q2 2018, up from 55 in Q1 2018.
- Funds reported $309M of Dova Pharmaceuticals, Inc. Common Stock stock for Q2 2018, up 12% quarter-over-quarter.
- 18 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 13 closed out, a net change of +5 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was BlackRock, an estimated $13.5M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was EcoR1 Capital, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2018.